A recent retrospective analysis by Ridker et al. [205] reveal an unexpected dramatic reduction in the number of incident cases of lung cancer in the large, randomized CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) originally designed to test the hypothesis that canakinumab, an interleukin 1β (IL-1β) inhibitory antibody, could reduce a secondary cardiovascular event in very high-risk patients with prior myocardial infarction and inflamed setting (i.e., C-reactive protein (CRP) levels > 2 mg/L) (Figure 3). Here, IL1B is linked to lung cancer.